INVESTORS

TSI is perfecting an Offering Memorandum for potential investments. The latest Offering is to fund conduct clinical trials in the United States and in Korea for the trans-Insulin Patch (Phase-3) and in various centers in the United States for the
Insulin patch.

---

TSI is a “C” corporation with investors in the United States and South Korea presently.
To request an Offering Memorandum please contact;
At Transdermal Specialties:
Bruce K. Redding, Jr. bredding@u-strip.com
Phone: 484-716-2165

---

CAPITAL ADVISORS